Related Experiment Video
Updated: May 5, 2026

Generic Protocol for Optimization of Heterologous Protein Production Using Automated Microbioreactor Technology
Published on: December 15, 2017
Coupling high-throughput and modeling approaches to streamline early-stage process development for biologics
John P Welsh1, Scott H Altern2,3, Jessica Y Lyall4
1Process Research and Development, Merck & Co., Inc., Rahway, New Jersey, USA.
This study introduces a novel workflow for monoclonal antibody (mAb) process development, integrating high-throughput screening and mechanistic modeling. This approach accelerates development and enhances process understanding without traditional lab-scale columns.
Area of Science:
- Biopharmaceutical Process Development
- Chromatographic Separations
- Protein Purification
Background:
- Downstream process development for monoclonal antibodies (mAbs) traditionally uses lab-scale methods, leading to lengthy timelines.
- Increasing complexity of biologics necessitates streamlined and efficient development strategies.
- Automated high-throughput screening and mechanistic modeling are emerging as powerful tools in bioprocessing.
Purpose of the Study:
- To propose and validate a streamlined workflow for early-stage downstream process development.
- To integrate high-throughput screening and mechanistic modeling for accelerated development.
- To reduce timeline and material requirements in bioprocess development.
Main Methods:
- Utilized automated resin plate screens for condition screening and parameter calibration.
- Employed mechanistic modeling to define robust process conditions for manufacturing.
- Confirmed process space using miniaturized RoboColumns, avoiding traditional lab-scale columns.
- Applied the workflow to cation-exchange (CEX) and multimodal cation-exchange (MMCEX) processes.
Main Results:
- The integrated workflow successfully narrowed screening conditions and calibrated binding isotherm parameters.
- Mechanistic models accurately characterized a robust range of conditions for early manufacturing.
- Miniaturized RoboColumns confirmed the predicted process space.
- Demonstrated utility for both CEX and MMCEX processes, predicting mAb product and aggregate impurities.
- Model-predicted parameter sensitivities aligned with traditional design-of-experiment (DOE) models.
Conclusions:
- The proposed workflow offers a practical and efficient roadmap for early downstream process development.
- This approach significantly reduces development timelines and material consumption.
- Enhanced process understanding is achieved through the integration of high-throughput screening and mechanistic modeling.
More Related Videos
Related Concept Videos
Biopharmaceutics and Pharmacokinetics: Overview
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Biopharmaceutical Factors Influencing Drug Product Design: Overview
Bioreactor Controls-III
Designing Growth Media for Bioreactors
Upstream Processing

